Fc-g receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer

Clinical Cancer Research

Volumn 22, Issue 10, 2016, Pages 2435-2444

  Liu, Geoffrey ^a   Tu, Dongsheng ^b   Lewis, Marcia ^c   Cheng, Dangxiao ^a   Sullivan, Leslie A ^c   Chen, Zhuo ^a   Morgen, Eric ^a   Simes, John ^d   Price, Timothy J ^e   Tebbutt, Niall C ^f   Shapiro, Jeremy D ^g   Jeffery, G Mark ^h   Mellor, J Daniel ⁱ   Mikeska, Thomas ^i,j,k   Virk, Shakeel ^b   Shepherd, Lois E ^b   Jonker, Derek J ^l   O'Callaghan, Christopher J ^b   Zalcberg, John R ⁱ   Karapetis, Christos S ^m   Dobrovic, Alexander ^i,j,k   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c TRANSGENOMIC INC   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f AUSTIN HEALTH   (Australia)

^g MONASH UNIVERSITY   (Australia)

^h CHRISTCHURCH HOSPITAL   (New Zealand)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^k LA TROBE UNIVERSITY   (Australia)

^l UNIVERSITY OF OTTAWA   (Canada)

^m FLINDERS UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; FC RECEPTOR; FC RECEPTOR IIA; EPIDERMAL GROWTH FACTOR RECEPTOR; FCGR2A PROTEIN, HUMAN; FCGR3A PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; RAS PROTEIN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; FCGR GENE; FCGR2A R GENE; FCGR3A GENE; FEMALE; GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SOMATIC MUTATION; SURVIVAL TIME; TREATMENT RESPONSE; VALIDATION PROCESS; CLINICAL TRIAL; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CETUXIMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, IGG; RETROSPECTIVE STUDIES;

EID: 84968821027     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0414     Document Type: Article

References (24)

1. Jonker DJ, O'Callaghan CJ, Karapetis Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040-8.
2. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
3. Qiu LX, Mao C, Zhang J, Zhu XD, Liao RY, Xue K, et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Eur J Cancer 2010; 46:2781-7.
4. Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibodydependent cell-mediated cytotoxicity. J Biomed Biotechnol 2011;2011: 379123.
5. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.
6. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317-27.
7. Clynes R. Antitumor antibodies in the treatment of cancer. Fc receptors link opsonic antibody with cellular immunity. Hematol Oncol Clin North Am 2006;20:585-612.
8. Gessner JE, Heiken H, Tamm A, Schmidt RE. The IgG Fc receptor family. Ann Hematol 1998;76:231-48.
9. Warmerdam PA, van de Winkel JG, Vlug A, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol 1991;147:1338-43.
10. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G Fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-96.
11. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 2001;276:16469-77.
12. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 2000; 406:267-73.
13. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of Fc-gamma-RIIa-Fc-gamma-RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122-9.
14. Dahan L, Norguet E, Etienne-Grimaldi MC, Formento JL, Gasmi M, Nanni I, et al. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer 2011;11:496.
15. Etienne-Grimaldi MC, Bennouna J, Formento JL, Douillard JY, Francoual M, Hennebelle I, et al. Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. Br J Clin Pharmacol 2012;73: 776-85.
16. Paez D, Pare L, Espinosa I, Salazar J, del Rio E, Barnadas A, et al. Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy? Cancer Sci 2010;101:2048-53.
17. Rodriguez J, Zarate R, Bandres E, Boni V, Herńandez A, Sola JJ, et al. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. Eur J Cancer 2012;48: 1774-80.
18. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25:3712-8.
19. Zhang W, Azuma M, Lurje G, Gordon MA, Yang D, Pohl A, et al. Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res 2010;30:4209-17.
20. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067-72.
21. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 2013;6:1.
22. Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, et al. FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 2011;22: 1302-7.
23. Kjersem JB, Skovlund E, Ikdahl T, Guren T, Kersten C, Dalsgaard AM, et al. FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab. BMC Cancer . 2014;14:340.
24. Geva R, Vecchione L, Kalogeras KT, Jensen BV, Lenz HJ, Yoshino T, et al. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut 2015; 64:921-8.